Cargando...
Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registr...
Gardado en:
| Publicado en: | Multidiscip Respir Med |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5950183/ https://ncbi.nlm.nih.gov/pubmed/29785264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40248-018-0126-7 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|